Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on August 3, 2021. The report discloses a specific corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel changes rather than financial performance.
Material Changes
- Director Departure: Mr. Michael Bonney resigned from the Board of Directors effective August 3, 2021.
- Reason for Departure: The resignation was in connection with his appointment as Executive Chairman of Alnylam Pharmaceuticals Inc.
- Board Composition: Effective August 3, 2021, the Board set the number of directors at ten.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the reduction to ten members.
- Confirm the appointment of Mr. Michael Bonney as Executive Chairman of Alnylam Pharmaceuticals Inc.
- Review subsequent filings for any impact on corporate governance or strategic direction resulting from this leadership change.